Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD)

NCT04612790 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04612790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04612790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2021
Completion date
October 26, 2023
Enrollment
67 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

bullous pemphigoid